Please Wait.....
Report
Global Hepatitis B Infection Market
Market Report I 2024-09-01 I 256 Pages I Data Bridge Market Research
The global hepatitis B infection market is expected to reach USD 18.21 billion by 2031 from USD 12.11 billion in 2023, growing at a CAGR of 5.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America)- Industry Trends and Forecast to 2031
Overview of Global Hepatitis B infection Market Dynamics:
Driver
- Increasing prevalence of hepatitis B infections
Restraint
- Side effects and drug resistance
Opportunity
- Advanced research and development for clinical trials
Market Players:
The key market players operating in the global hepatitis B infection market are listed below:
- Gilead Sciences, Inc.
- GSK plc
- Dynavax Technologies
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb
- Merck Sharp and Dohme Corp.
- Novartis AG
- Arrowhead Pharmaceuticals Inc.
- Arbutus Biopharma
- Teva Pharmaceuticals, Inc.
- Zydus Pharmaceuticals
- Aurobindo Pharma
- Lupin Pharmaceuticals, Inc.
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF GLOBAL HEPATITIS B INFECTION MARKET 23
1.4 MARKETS COVERED 26
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 THERAPEUTICS LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 VENDOR SHARE ANALYSIS 38
2.11 SECONDARY SOURCES 39
2.12 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHT 46
4.1 PESTAL ANALYSIS 48
4.2 PORTER FIVE FORCES 49
5 GLOBAL HEPATITIS B INFECTION MARKET: REGULATIONS 50
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 50
5.2 NORTH AMERICA REGULATORY SCENARIO 58
5.3 EUROPE REGULATORY SCENARIO 66
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 70
5.5 SOUTH AMERICA REGULATORY SCENARIO 75
6 PIPELINE ANALYSIS 80
7 EPIDEMILIOGY 91
8 MARKET OVERVIEW 93
8.1 DRIVERS 95
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 95
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 96
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 97
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 98
8.2 RESTRAINTS 99
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 99
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 100
8.3 OPPORTUNITY 101
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 101
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 102
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 103
8.4 CHALLENGES 104
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 104
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 105
9 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE 106
9.1 OVERVIEW 107
9.2 CHRONIC 110
9.3 ACUTE 110
10 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT 111
10.1 OVERVIEW 112
10.2 VACCINE 115
10.2.1 HOSPITAL PHARMACIES 115
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 115
10.2.3 ONLINE PHARMACIES 115
10.3 ANTIVIRAL DRUGS 116
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 116
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 116
10.3.3 ENTECAVIR 116
10.3.4 OTHERS 116
10.4 IMMUNE MODULATOR DRUGS 117
10.4.1 PEGYLATED INTERFERON 117
10.4.2 INTERFERON ALPHA 117
10.5 SURGERY 118
11 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION 119
11.1 OVERVIEW 120
11.2 NORTH AMERICA 123
11.2.1 U.S 125
11.2.2 CANADA 127
11.2.3 MEXICO 129
11.3 SOUTH AMERICA 131
11.3.1 BRAZIL 133
11.3.2 ARGENTINA 135
11.3.3 REST OF SOUTH AMERICA 137
11.4 MIDDLE EAST AND AFRICA 138
11.4.1 SOUTH AFRICA 140
11.4.2 SAUDI ARABIA 142
11.4.3 EGYPT 144
11.4.4 KUWAIT 146
11.4.5 QATAR 148
11.4.6 U.A.E 150
11.4.7 OMAN 152
11.4.8 BAHRAIN 154
11.4.9 REST OF MIDDLE EAST AND AFRICA 156
11.5 ASIA-PACIFIC 157
11.5.1 CHINA 160
11.5.2 INDIA 162
11.5.3 INDONESIA 164
11.5.4 JAPAN 166
11.5.5 VIETNAM 168
11.5.6 PHILIPPINES 170
11.5.7 THAILAND 172
11.5.8 SOUTH KOREA 174
11.5.9 AUSTRALIA 176
11.5.10 SINGAPORE 178
11.5.11 MALAYSIA 180
11.5.12 NEW ZEALAND 182
11.5.13 TAIWAN 184
11.5.14 REST OF ASIA-PACIFIC 186
11.6 EUROPE 187
11.6.1 GERMANY 190
11.6.2 U.K 192
11.6.3 TURKEY 194
11.6.4 RUSSIA 196
11.6.5 SPAIN 198
11.6.6 ITALY 200
11.6.7 SWEDEN 202
11.6.8 BELGIUM 204
11.6.9 POLAND 206
11.6.10 FRANCE 208
11.6.11 SWITZERLAND 210
11.6.12 NETHERLANDS 212
11.6.13 NORWAY 214
11.6.14 DENMARK 216
11.6.15 FINLAND 218
11.6.16 REST OF EUROPE 220
12 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 221
12.1 COMPANY SHARE ANALYSIS: GLOBAL 221
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 222
12.3 COMPANY SHARE ANALYSIS: EUROPE 223
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 224
13 SWOT ANALYSIS 225
14 COMPANY PROFILE 226
14.1 GILEAD SCIENCES, INC. 226
14.1.1 COMPANY SNAPSHOT 226
14.1.2 REVENUE ANALYSIS 226
14.1.3 COMPANY SHARE ANALYSIS 227
14.1.4 PRODUCT PORTFOLIO 227
14.1.5 RECENT DEVELOPMENT 227
14.2 GLAXOSMITHKLINE PLC 229
14.2.1 COMPANY SNAPSHOT 229
14.2.2 REVENUE ANALYSIS 229
14.2.3 COMPANY SHARE ANALYSIS 230
14.2.4 PRODUCT PORTFOLIO 230
14.2.5 RECENT DEVELOPMENT 230
14.3 DYNAVAX TECHNOLOGIES CORPORATION 232
14.3.1 COMPANY SNAPSHOT 232
14.3.2 REVENUE ANALYSIS 232
14.3.3 COMPANY SHARE ANALYSIS 233
14.3.4 PRODUCT PORTFOLIO 233
14.3.5 RECENT DEVELOPMENTS 233
14.4 F. HOFFMAN-LA ROCHE LTD. 235
14.4.1 COMPANY SNAPSHOT 235
14.4.2 REVENUE ANALYSIS 235
14.4.3 COMPANY SHARE ANALYSIS 236
14.4.4 PRODUCT PORTFOLIO 236
14.4.5 RECENT DEVELOPMENTS 236
14.5 BRISTOL-MYERS SQUIBB COMPANY 237
14.5.1 COMPANY SNAPSHOT 237
14.5.2 REVENUE ANALYSIS 237
14.5.3 COMPANY SHARE ANALYSIS 238
14.5.4 PRODUCT PORTFOLIO 238
14.5.5 RECENT DEVELOPMENTS 238
14.6 ARROWHEAD PHARMACEUTICALS, INC. 239
14.6.1 COMPANY SNAPSHOT 239
14.6.2 REVENUE ANALYSIS 239
14.6.3 PRODUCT PORTFOLIO 240
14.6.4 RECENT DEVELOPMENTS 240
14.7 ARBUTUS BIOPHARMA 241
14.7.1 COMPANY SNAPSHOT 241
14.7.2 REVENUE ANALYSIS 241
14.7.3 PRODUCT PORTFOLIO 242
14.7.4 RECENT UPDATES 242
14.8 AUROBINDO PHARMA 243
14.8.1 COMPANY SNAPSHOT 243
14.8.2 REVENUE ANALYSIS 243
14.8.3 PRODUCT PORTFOLIO 244
14.8.4 RECENT UPDATES 244
14.9 LUPIN PHARMACEUTICALS, INC. 245
14.9.1 COMPANY SNAPSHOT 245
14.9.2 PRODUCT PORTFOLIO 245
14.9.3 RECENT UPDATES 246
14.10 MERCK & CO., INC., 247
14.10.1 COMPANY SNAPSHOT 247
14.10.2 REVENUE ANALYSIS 247
14.10.3 PRODUCT PORTFOLIO 248
14.10.4 RECENT DEVELOPMENTS 248
14.11 NOVARTIS AG 249
14.11.1 COMPANY SNAPSHOT 249
14.11.2 REVENUE 249
14.11.3 PRODUCT PORTFOLIO 250
14.11.4 RECENT DEVELOPMENT 250
14.12 TEVA PHARMACEUTICAL INDUSTRIES 251
14.12.1 COMPANY SNAPSHOT 251
14.12.2 PRODUCT PORTFOLIO 251
14.12.3 RECENT DEVELOPMENTS 251
14.13 ZYDUS PHARMACEUTICALS, INC. 252
14.13.1 COMPANY SNAPSHOT 252
14.13.2 PRODUCT PORTFOLIO 252
14.13.3 REVENUE 253
14.13.4 RECENT DEVELOPMENT 253
15 QUESTIONNAIRE 254
16 RELATED REPORTS 256
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security